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Aim: To investigate prevalence of arrythmias and thromboembolic events, as well as long term out-
comes among patients diagnosed and treated of non-compaction cardiomyopathy (NCC) according to 
current recommendations in University Hospital Centre (UHC) Zagreb. 
Patients and Methods: A single center retrospective study was conducted. Patients newly diagnosed 
with NCC in UHC Zagreb during period 2009-2018 were analyzed. The diagnosis was confirmed by both 
echocardiography and cardiovascular magnetic resonance. Hospital database and charts were used 
for clinical data, echocardiography data was obtained from digital database using EchoPac. Patients 
were followed-up clinically and by the means of echocardiography. 
Results: 32 patients (pts), 18 men (53.25 %) were included. At the 
time of diagnosis (baseline), mean age was 47.7±15.4 years, ma-
jority of pts (84.38% of pts, N=27) were in functional NYHA class 
≥2, with mean NT-proBNP values of 3870±6619 ng/L. Echocar-
diography revealed reduced left ventricular systolic function; 
baseline ejection fraction (EF) was 27.52±11.94%. Patients were 
discharged with heart failure therapy: beta-blockers (30 pts, 
93.75%), angiotensin-converting enzyme inhibitors or angio-
tensin receptor blockers (29 pts, 90.63%), angiotensin receptor–
neprilysin inhibitor (1 pts, 3.13%), mineralocorticoid receptor 
antagonists (28 pts, 84.38%); and 26 pts (81.25%) required symp-
tomatic diuretic use. Cardiac resynchronization therapy with 
defibrillator was implanted in 11 pts (34.38%) and implantable 
cardioverter defibrillator (ICD) in 16 pts (50%). At baseline, 9 pts 
(28.13%) were already receiving anticoagulation due to previous 
thromboembolic events (Table 1). At discharge, 17 pts (53.13%) 
were anticoagulated (warfarin in 14 pts, 82.35%, novel direct 
oral anticoagulants in 3 pts, 17.65%). Mean follow-up period 
was 3.42±3.31 years. At the end of follow up period, functional 
improvement was observed: 21.88% (N=7) pts were in NYHA ≥2 
status (p<0.05), with manifest, but statistically nonsignificant 
reduction of NT-proBNP levels (1260±2266 ng/L, p=0.063). Con-
trol echocardiography revealed significant improvement in EF 
(40.24±11.39%, p<0.001). There were no new thromboembolic 
events. While arrythmias were common at the time of diagno-
sis (Table 1), there was only one ICD activation during follow-up. None of the pts have died, 1 patient 
received heart transplant and 2 were implanted with left ventricular assist device. 
Conclusion: Optimal medical treatment in patients with NCC1 corresponds with good long-term out-
comes, functional improvement, and low risk of recurrent thromboembolic events or malignant ar-
rythmias. 
tABLe 1. Number of patients diagnosed with thromboembolic 
events and arrythmias at the time of diagnosis and at the end 
of the follow-up period.
Number of patients: At diagnosis At follow up
THROMBOEMBOLIC EVENTS
Left ventricular thrombus 3 (9.38%) 0 (0)
Stroke/TIA 4 (12.50%) 0 (0)
Other embolus 1 (3.13%) 0 (0)
ARRYTHMIAS
Atrial fibrillation 3 (9.38%) 7 (21.88%)
nsVT 15 (46.88%) 8 (25.00%)
Sustained VT 1 (3.13%) 4 (12.50%)
ICD activation 0 (0%) 1 (6.25%) 
TIA = transient ischemic attack; nsVT = non-sustained ventricular tachycardia; VT = 
ventricular tachycardia; ICD = implantable cardioverter defibrillator.
